Genmab — Februar 2019

[Raun]

Håber i hvert fald at et spirende forår, kan være = en spirende uptrend.............. Men det tør man jo næsten ikke håbe på, og rent omsætning mæssigt. Så kan man jo heller ikke tro helhjjertet på dette...

[Helge_LarsenPI-redaktør]

Uptrenden starter når vi har brudt 1020.

[Darvin]

Sådan - frisk fra leveren - vil jeg sige... nogen her ynder jo at leve efter devisen Den man elsker tugter man, men der går sjældent røg af en brand uden ild, Gammel kærlighed ruster jo ikke og tiden læger alle sår så bagefter er vi alle kloge og den der ler sidst ler bedst. Lad os nu se, sagde den blinde til den døve, alt godt kommer til den der venter. Snart god weekend.

[Den_Fattige]

hmmm... det var vist toppen for denne gang. synes godt nok at den ser noget slap ud. overvejer at gå på weekden med "tom tank"

[gdn55]

Nej det er nu det begynder, så fyld din tank igen.

[E_L]

New trial (by Shaji Kumar) Daratumumab and Dexamethasone With Pomalidomide or Carfilzomib in Treating Patients With Relapsed Multiple Myeloma https://clinicaltrials.gov/ct2/show/NCT03841565?term=daratumumab+OR+ofatumumab+OR+tisotumab+OR+arzerra+OR+darzalex&lupd_s=02%2F15%2F2019&rank=1

[E_L]

Pollux completion date extended by half a year https://clinicaltrials.gov/ct2/history/NCT02076009?A=39&B=40&C=merged

[E_L]

I think they are giving MAIA participants on (Rd) arm who have sponsor-confirmed disease progression , the option to receive daratumumab https://clinicaltrials.gov/ct2/history/NCT02252172?A=47&B=48&C=merged

[E_L]

ethical decision?

[E_L]

ALL hospitals now recruiting in the HuMax-AXL-ADC trial (1 hospital removed) https://clinicaltrials.gov/ct2/history/NCT02988817?A=11&B=12&C=merged

[Solsen]

Full speed

[Bulder]

E L 17:41: That is the cross over problem we have discussed earlier. When they do that they

[Bulder]

will never get a reliable OS, as there is no control group to compare with.

[Bulder]

But maybe they have realized that Rd-pts would do it any way (cross over).

[E_L]

maybe. i guess you can not stop them from taking Dara if they want to.

[E_L]

...just for the purpose of a 'clean' trial

[Bulder]

xactly, they can leave the study any time and pay for dara themselves. But now Janssen will pay for them. Nice move.

[Helge_LarsenPI-redaktør]

Just a moment...

(www.proinvestor.com)

[peter12]

Interessant artikel om atezo + dara https://www.medpagetoday.com/reading-room/asco/immunotherapy/78028

[peter12]

Og det må være dette forsøg der er udvidet ? https://clinicaltrials.gov/ct2/show/NCT02431208?cond=NCT02431208&rank=1